- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT01664273
Gene Electrotransfer to Muscle With Plasmid AMEP in Patients With Disseminated Cancer
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
Cohorts of 3 patients will be treated with increasing doses of plasmid AMEP. Up to 12 patients will be treated.
Treatment procedure: Local anesthetic is applied to m. quadriceps femoris (thigh muscle) and the skin. An incision of the skin is performed followed by dissection until the muscle is exposed. The surgical procedure is performed by plastic surgeons.
Plasmid AMEP is injected intramuscularly and immediately followed by application of electric pulses via a needle electrode inserted into the muscle. A combination of one high voltage pulse (700V/cm, 100 µs) followed by one low voltage pulse (80 V/cm, 400 ms) will be applied. The wound is sutured and a dressing is applied. Treatment procedure is estimated to 30 minutes.
All patients are hospitalized for 24 hours after treatment for the purpose of evaluation of vital signs, physical examination, AE and SAE recording and pharmacokinetics sampling (blood and urine).
Blood biochemistry including LDH and CK is taken 24 hours post treatment. ECG will be taken before and after treatment. Patients score discomfort or pain from treated area using VAS.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 1
Kontakte und Standorte
Studienorte
-
-
-
Herlev, Dänemark, 2730
- Depart. of Oncology, Copenhagen Universtiy Hospital Herlev
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Age > 18 years.
- Performance status < 1 (ECOG).
- Histologically confirmed malignant tumor (solid tumor) of any histology,
- Metastatic disease. Patients with asymptomatic brain metastases are eligible.
- Patient should have been offered standard treatment. Patient is eligible if no standard treatment is available or if the patient does not wish to receive standard treatment.
- Life expectancy ≥ 3 months.
- Measurable disease defined as at least one measurable lesion according to RECIST 1.1
- Patient should have adequate organ function:
- Adequate bone marrow function: Neutrophil count ≥ 1.0 x 109/l (≤ grade 2 CTCAE 4.0); Platelet count ≥ 75 x 109/l (< grade 2 CTCAE 4.0); Hemoglobin ≥ 6,0 mmol/l.
- Liver: ALAT or ASAT < 3 ULN (< grade 2 CTCAE 4.0); Bilirubin ≤ 1,5 ULN (< grade 2 CTCAE 4.0); APTT within normal range; INR ≤ 1,2 (< grade 1 CTCAE 4.0)
- Kidney: Plasma creatinin ≤ 1.5 ULN (< grade 2 CTCAE 4.0)
- At least 4 weeks since any anti-cancer treatment.
- Men and women of reproductive age must use effective contraception during the study and at least 6 months after administration of plasmid AMEP.
- Patient should be able to understand the participant information and able to comply with protocol requirements and scheduled visits.
- Signed informed consent.
Exclusion Criteria:
- Allergy to the anaesthetic used.
- Clinical signs of active infection.
- Implanted pacemaker, defibrillator or any other implanted electronic device.
- Participation in other clinical trials involving experimental drugs or participation in a clinical trial within 4 weeks before initiation of study treatment.
- AMI (acute myocardial infarction), stroke or acute ischemic event within the last 6 months.
- Severe atherosclerosis, significant cardiovascular disease (NYHA III or IV) or significant arrhythmias.
- Systolic blood pressure above 180 mm Hg and/or diastolic blood pressure above 110 mm Hg. If BP >180/110 mm Hg medical correction is allowed and the patient can be included when BP < 180/110 mm Hg.
- Pregnancy and lactation.
- Clinically significant coagulopathy.
- Treatment with anticoagulant drugs.
- Other disorders which the investigator finds incompatible with participation in the study.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Safety of the trial treatment
Zeitfenster: From treatment to last follow up, planned 8 weeks.
|
Safety is evaluated by registration of adverse events (Adverse Events and Serious Adverse Events) using the CTCAE criteria version 4.0.
Patients are seen in the out patient clinic once a week during the first month after treatment (at day 8, day 15, day 22, day 29) and 8 weeks after treatment.
If no progression of the disease at 8 weeks, patients are seen at 12 weeks and then every three months until disease progression or death.
|
From treatment to last follow up, planned 8 weeks.
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Efficacy of the trial treatment
Zeitfenster: PET/CT scan 4 weeks, 8 weeks and 12 weeks after trial treatment.
|
PET/CT scan will be evaluated using RECIST 1.1 (CT) and PERCIST (PET)
|
PET/CT scan 4 weeks, 8 weeks and 12 weeks after trial treatment.
|
Pharmacokinetics
Zeitfenster: Pre-dose, 2, 6 and 24 hours after dose, day 8, 15, 22, 29 and 8 weeks after treatment.
|
Measurements of plasma and urine plasmid AMEP concentrations.
Measurements of plasma and urine protein AMEP concentrations
|
Pre-dose, 2, 6 and 24 hours after dose, day 8, 15, 22, 29 and 8 weeks after treatment.
|
Discomfort associated with the treatment procedure
Zeitfenster: Scoring 'immediately after treatment', '30 min after treatment' '6 hours after treatment' and 'pain in the past 24 hours', and day 8.
|
The patient completes VAS (Visual Analogue Scale) scores pain related to the treatment area at abovementioned time points.
|
Scoring 'immediately after treatment', '30 min after treatment' '6 hours after treatment' and 'pain in the past 24 hours', and day 8.
|
Safety
Zeitfenster: Day after treatment and 14 days after treatment
|
MR scan of treated region (thigh muscle) in order to assess potential intramuscular edema or hematoma
|
Day after treatment and 14 days after treatment
|
Mitarbeiter und Ermittler
Ermittler
- Hauptermittler: Julie Gehl, MD DMSci, Department of Oncology, Copenhagen University Hospital Herlev
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Voraussichtlich)
Studienabschluss (Voraussichtlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- AA 1201
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Metastasierendes bösartiges Neoplasma
-
John MascarenhasNational Cancer Institute (NCI); National Institutes of Health (NIH); Celgene... und andere MitarbeiterAbgeschlossenIDH2-Mutation | Accelerated/Blast-phase Myeloproliferative Neoplasm | Myelofibrose in der chronischen PhaseVereinigte Staaten, Kanada
Klinische Studien zur Plasmid AMEP
-
AnGes USA, Inc.AbgeschlossenIschämie | Periphere Gefäßerkrankung | Arterielle VerschlusskrankheitVereinigte Staaten
-
Rigshospitalet, DenmarkAbgeschlossenIschämische HerzerkrankungDänemark
-
Histograft Co., Ltd.Moscow State University of Medicine and DentistryAbgeschlossenKnochenschwund | Zahnverlust | Knochenzysten | Knochenbruch | Knochendeformität | KnochenatrophieRussische Föderation
-
AnGes USA, Inc.AbgeschlossenIschämie | Periphere Gefäßerkrankung | Arterielle Verschlusskrankheit | GeschwüreVereinigte Staaten
-
AnGes USA, Inc.AbgeschlossenGefäßerkrankungen | Periphere arterielle Verschlusskrankheit | Kritische ExtremitätenischämieVereinigte Staaten
-
Beijing Northland Biotech. Co., Ltd.RekrutierungIschämie | Periphere Gefäßerkrankung | Arterielle Verschlusskrankheit | GeschwüreChina
-
Ludwig Institute for Cancer ResearchM.D. Anderson Cancer Center; Memorial Sloan Kettering Cancer Center; New York...AbgeschlossenSarkom | Speiseröhrenkrebs | Prostatakrebs | Blasenkrebs | Nicht-kleinzelligem LungenkrebsVereinigte Staaten
-
Memorial Sloan Kettering Cancer CenterNational Cancer Institute (NCI)AbgeschlossenMelanom (Haut)Vereinigte Staaten
-
AnGes USA, Inc.BeendetKritische ExtremitätenischämieVereinigte Staaten, Frankreich, Belgien, Kanada, Polen, Finnland, Dänemark, Niederlande, Ungarn, Italien, Schweden
-
H. Lee Moffitt Cancer Center and Research InstituteNational Gene Vector LaboratoryAbgeschlossenBösartiges MelanomVereinigte Staaten